Currently Viewing:
Newsroom
Currently Reading
Researchers Characterize Epidemiology of, Source of Infection in Febrile Neutropenia
February 16, 2019 – Jaime Rosenberg
Continuous Fingolimod Treatment Leads to 50% Reduction of ARRs
February 15, 2019 – Samantha DiGrande
CMS Proposes That Patients Be Enrolled in Studies to Get Coverage for CAR T-Cell Therapy
February 15, 2019 – Mary Caffrey and Allison Inserro
What We're Reading: Syphilis Rates Rising; House Democrats and ACA Suit; WHO to Look at Gene Editing
February 15, 2019 – AJMC Staff
HCCI Report: Healthcare Spending Increased Even as Utilization Decreased or Stagnated
February 15, 2019 – Wallace Stephens
AJMC® in the Press, February 15, 2019
February 15, 2019 – AJMC Staff
5 Findings From the February 2019 Issue of AJMC®
February 15, 2019 – Christina Mattina
This Week in Managed Care: February 15, 2019
February 15, 2019
Adding COPD Screenings to Drug Clinic Appointments Yields Benefits for Patients
February 15, 2019 – Allison Inserro

New Device, With Localized Drug Delivery to Pancreatic Tumors, Could Reduce AE

Surabhi Dangi-Garimella, PhD
Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.
Pancreatic cancer is a disease with dismal survival rates (less than 5%) and the second only to non-small cell lung cancer for cancer-related deaths in the United States. A major challenge with treating this disease has been the stromal milieu that surrounds the solid tumor and forms a rigid, impenetrable barrier for chemotherapy. Now, scientists at the University of North Carolina at Chapel Hill have developed a technology that, at least in animal models, has found an Achilles Heel in these tumors.

The researchers have invented an implantable device that can deliver the highly toxic and promising drug cocktail of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (together called FOLFIRINOX), directly to the tumor.

“We use the device to hit the primary tumor hard. It’s an exciting approach because there is so little systemic toxicity that it leaves room to administer additional drugs against cancer cells that may have spread in the rest of the body,” according to senior author Jen Jen Yeh, MD, senior author on the study.

According to the paper, published in the Proceedings of the National Academy of Sciences, the iontophoretic device was surgically implanted onto orthotopic patient-derived pancreatic tumors in mice, and the animals were administered saline or FOLFIRINOX through the device, or saline or FOLFIRINOX intravenously (IV). Tumor volumes were measured following treatment completion.

The authors found that 50% of mice who received FOLFIRINOX through the device had significant tumor regression and 1 mouse had stable disease. The mean log2-fold change in tumor volume were 0.4 in mice that received device FOLFIRINOX, 1.9 for IV FOLFIRINOX, 3 for IV saline, and 2.6 for device saline. Additionally, when the tumor tissues were stained for a cell proliferation marker, Ki-67, mice who received FOLFIRINOX through the device had significantly lower expression of the marker, indicating regression of tumor growth. Another important finding of the study was the reduced levels of tissue toxicity with the implanted device, which indicates that these toxic drugs may be better tolerated by patients, and might even improve their quality of life.

“The beauty of this device is that all of the drug delivery is focused locally, with low delivery to the rest of the body,” said James D. Byrne, PhD, the paper’s first author. “If this works in humans, we hope the device can be used as a plug-and-play approach to delivering the latest, most promising drug regimens for patients who have a dire need for new and better treatments.”

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!